Sugammadex can be part of the solution. Let's not make it part of the problem!

Minerva Anestesiologica

Volumn 79, Issue 6, 2013, Pages 587-589

  Vannucci, A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROCURONIUM; SUGAMMADEX; VECURONIUM;

ALLERGIC REACTION; ANESTHESIST; CLINICAL EXAMINATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; EDITORIAL; ERYTHEMA; FIBERSCOPE ENDOSCOPY; FLUSHING; GENERAL ANESTHESIA; HUMAN; NERVE STIMULATION; POSTOPERATIVE CARE; RESPIRATORY TRACT INTUBATION; SIDE EFFECT;

ANESTHESIA, GENERAL; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKING AGENTS;

EID: 84881439310     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Della Rocca G, Di Marco P, Beretta L, De Gaudio AR, Ori C, Mastronardi P. Do we need use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use. Minerva Anestesiol 2013;79:661-6.
2. Abrishami A, Ho J, Wong J, Yin L, Chung F. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Anesth Analg 2010;110:1239.
3. Duvaldestin P, Plaud B. Sugammadex in anesthesia practice. Expert opinion Pharmacother 2010;11:2759-71.
4. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg 2010;111:120-8.
5. Raccomandazioni per la sicurezza in sala operatoria 4.5 Obiettivo 5. Prevenire i danni da anestesia garantendo le funzioni vitali. p. 16-7.]
6. Standard per il monitoraggio in anesthesia (edizione 2012) 3.4 Funzione neuromuscolare [Internet]. Available at http://siaarti.it/informa/informa-leggi. php?page=ibrma&id=138 [cited 2013, Apr 15].
7. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg 2010;111:110-9.
8. Fuchs-Buder T, Meistelman C: [Monitoring of neuromuscular block and prevention of residual paralysis]. Annales francaises d'anesthesie et de reanimation 2009(28 Suppl 2):S46-50.
9. Kopman AF. Managing neuromuscular block: where are the guidelines? Anesth Analg 2010;111:9-10.
10. Kopman AF. Neostigmine versus sugammadex: which, when, and how much? Anesthesiology 2010;113:1010-1.
11. Kopman AF, Kurata J. Can't intubate, can't ventilate: is "rescue reversal" a pipe-dream? Anesth Analg 2012;114:924-6.
12. Kopman AF, Kurata J. Rescue reversal: an addendum. Anesth Analg 2012;115:1254-55.
13. Watts RW, London JA, van Wijk RM, Lui YL. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. Anaesth Intensive Care 2012;40:333-9.
14. Ledowski T, Hillyard S, Kozman A, Johnston F, Gillies E, Greenaway M et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intens Care 2012;40:340-343.
15. Fuchs-Buder T, Meistelman C, Schreiber JU. Is sugammadex economically viable for routine use. Curr Opin Anaesthesiol 2012, 25(2):217-220.
16. Paton F, Paulden M, Chambers D et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. British journal of anaesthesia 2010, 105(5):558-567.
17. Chambers D, Paulden M, Paton F et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health technology assessment (Winchester, England) 2010, 14(39):1-211.
18. Advice - sugammadex (Bridion) [http://www.scottishmedicines.org.uk/files/ sugammadex-Bridion-FINAL-for-Website.pdf]